Skip to main content
Have a personal or library account? Click to login
The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells Cover

The comparison of cytotoxicity of the anticancer drugs doxorubicin and ellipticine to human neuroblastoma cells

Interdisciplinary Toxicology
Volume 1 (2008): Issue 2 (September 2008)
By: ,  ,  ,   and    
Open Access
|Nov 2010
References

References

  1. Auclair C (1987) Multimodal action of antitumor agents on DNA: The ellipticine series.: 1-14.
    Open DOISearch in Google Scholar
  2. Bedrníček J, Vícha A, Jarošová M, Holzerová M, Činátl J Jr, Michaelis M, Činátl J, Eckschlager T (2005) Characterization of drug-resistant neuroblastoma cell lines by comparative genomic hybridization.: 415-419.
    Search in Google Scholar
  3. Borek-Dohalská L, Frei E, Stiborová M (2004) DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells.: 603-615.
    Open DOISearch in Google Scholar
  4. Brodeur GM (2003) Neuroblastoma: biological insights into a clinical enigma.: 203-216.
    Open DOISearch in Google Scholar
  5. Frei E, Bieler CA, Arlt VM, Wiessler M, Stiborová M (2002) Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes.: 289-295.
    Open DOISearch in Google Scholar
  6. Hardesty CT, Chaney NA, Mead JA (1972) The effect of route of administration on the distribution of ellipticine in mice.: 1884-1889.
    Search in Google Scholar
  7. Kotchetkov R, Cinatl J, Blaheta R, Vogel JU, Karaskova J, Squire J, Hernáiz Driever P, Klingebiel T, Cinatl J Jr (2003) Development of resistance to vincristine and doxorubicin in neuroblastoma alters malignant properties and induces additional karyotype changes: a preclinical model.: 36-43.
    Open DOISearch in Google Scholar
  8. Lesca P, Beaune P, Monsarrat B (1981) Ellipticines and human liver microsomes: spectral interaction with cytochrome P-450 and hydroxylation. Inhibition of arylhydrocarbon metabolism and mutagenicity.: 299-309.
    Search in Google Scholar
  9. Maris JM, Mathay KK (1999) Molecular biology of neuroblastomas.: 2264-2279.
    Search in Google Scholar
  10. Murray GI, Weaver RJ, Paterson PJ, Ewen SW, Melvin WT, Burke MD (1993) Expression of xenobiotic metabolizing enzymes in breast cancer.: 347-353.
    Open DOISearch in Google Scholar
  11. Stiborová M, Bieler CA, Wiessler M, Frei E (2001) The anticancer agent ellipticine on activation by cytochrome P450 forms covalent DNA adducts.: 1675-1684.
    Open DOISearch in Google Scholar
  12. Stiborová M, Stiborová-Rupertová M, Bořek-Dohalská L, Wiessler M, Frei E (2003a) Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans.: 38-47.
    Open DOISearch in Google Scholar
  13. Stiborová M, Breuer A, Aimová D, Stiborová-Rupertová M, Wiessler M, Frei E (2003b) DNA adduct formation by the anticancer drug ellipticine in rats determined byP-postlabeling.: 885-890.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/v10102-010-0036-9 | Journal eISSN: 1337-9569 | Journal ISSN: 1337-6853
Journal RSS Feed
Language: English
Page range: 186 - 189
Published on: Nov 1, 2010
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services
Keywords:
anticancer drug,
ellipticine,
doxorubicin,
human neuroblastoma cells,
cytotoxicity
Related subjects:
Medicine,
Clinical medicine,
Pharmacology, toxicology

© 2010 Jitka Poljaková, Tomáš Eckschlager, Jana Hřebačková, Jan Hraběta, Marie Stiborová, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons License.

Volume 1 (2008): Issue 2 (September 2008)
Previous article
Next article